PTCT250117C46000
- 2.25
- -0.35-13.46%
PTC Therapeutics Newsroom
PTC Therapeutics Raised to Overweight From Equal-Weight by Morgan Stanley
PTC Therapeutics Analyst Ratings
RBC Capital Maintains PTC Therapeutics(PTCT.US) With Buy Rating, Maintains Target Price $63
PTC Therapeutics (PTCT) Receives a Buy From RBC Capital
Morgan Stanley Maintains PTC Therapeutics(PTCT.US) With Buy Rating, Maintains Target Price $67
Morgan Stanley Upgrades PTC Therapeutics(PTCT.US) to Buy Rating, Raises Target Price to $67
PTC Therapeutics: Hold Rating Amid Strategic Collaboration With Novartis and Clinical Uncertainties
Citi Maintains PTC Therapeutics(PTCT.US) With Sell Rating, Raises Target Price to $32
PTC Therapeutics Is Maintained at Sell by Citigroup
Goldman Sachs Maintains Sell on PTC Therapeutics, Raises Price Target to $42
Barclays Maintains PTC Therapeutics(PTCT.US) With Hold Rating, Raises Target Price to $56
A Quick Look at Today's Ratings for PTC Therapeutics(PTCT.US), With a Forecast Between $41 to $68
UBS Raises PTC Therapeutics Price Target to $71 From $47, Maintains Buy Rating
PTC Therapeutics Is Maintained at Equal-Weight by Barclays
PTC Therapeutics Analyst Ratings
Baird Maintains Outperform on PTC Therapeutics, Raises Price Target to $70
Analysts Offer Insights on Healthcare Companies: Cytokinetics (CYTK), PTC Therapeutics (PTCT) and Vir Biotechnology (VIR)
PTC Therapeutics' Strategic Collaboration With Novartis Boosts Buy Rating
Hold Recommendation for PTC Therapeutics: Balancing Promising Prospects With Regulatory and Competitive Challenges
RBC Capital Remains a Hold on PTC Therapeutics (PTCT)